Predictive Oncology (NASDAQ:POAI) Share Price Passes Below 200-Day Moving Average of $5.06

Shares of Predictive Oncology Inc. (NASDAQ:POAI) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.06 and traded as low as $3.68. Predictive Oncology shares last traded at $3.74, with a volume of 24,195 shares trading hands.

Predictive Oncology Stock Performance

The firm has a market capitalization of $15.88 million, a price-to-earnings ratio of -0.80 and a beta of 1.54. The stock’s fifty day moving average is $5.03 and its two-hundred day moving average is $5.03.

Predictive Oncology (NASDAQ:POAI) last announced its earnings results on Thursday, August 10th. The medical instruments supplier reported ($0.95) earnings per share for the quarter. Predictive Oncology had a negative net margin of 1,246.52% and a negative return on equity of 90.72%. The business had revenue of $0.49 million for the quarter.

Institutional Trading of Predictive Oncology

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Predictive Oncology in the fourth quarter valued at $25,000. Charles Schwab Investment Management Inc. bought a new stake in Predictive Oncology in the 1st quarter valued at about $54,000. Citadel Advisors LLC acquired a new position in Predictive Oncology during the 3rd quarter valued at about $65,000. Renaissance Technologies LLC grew its position in Predictive Oncology by 26.9% in the 4th quarter. Renaissance Technologies LLC now owns 302,724 shares of the medical instruments supplier’s stock worth $93,000 after purchasing an additional 64,261 shares during the last quarter. Finally, RB Capital Management LLC increased its stake in shares of Predictive Oncology by 161.2% in the first quarter. RB Capital Management LLC now owns 416,693 shares of the medical instruments supplier’s stock valued at $136,000 after purchasing an additional 257,193 shares during the period. Institutional investors and hedge funds own 6.03% of the company’s stock.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.